The progesterone vaginal ring (PVR) is a contraceptive designed for use byC ontraceptive vaginal rings are a new product category in many developing countries. There are two contraceptive vaginal rings on the market: a three-monthly progesterone-containing ring available in a few countries in Central and South America under the brand name Progering R ; and a monthly etonogestrel/ethinyl estradiol ring sold under the brand name NuvaRing R in Europe, the United States, and other industrialized countries. Contraceptive vaginal rings offer particular benefits to users and health systems: users can self-insert and remove the ring, giving them greater control over how the product is used, while health systems benefit from the limited need for extensive clinical training, equipment, and supplies.

No abstract

No abstract

No abstract

In terms of utilization, the results generated will inform and guide next steps about product introduction. Specifically, the findings of this study will be integrated with results from a market segmentation exercise conducted earlier to develop a pricing model for the PVR. The price will reflect not only the cost of goods (COGS) and cost of product introduction (training, educational material, marketing and branding, demand creation) but also the benefits to the health system (e.g., limited need for infrastructure and equipment, potential for multiple service outlets and health cadres). The results will also be useful to refine PVR market segmentation and tailor specific strategies for product introduction, including innovative financing approaches.